Edge Rewrite
restyle Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

2C-iP

Add links
From Wikipedia, the free encyclopedia
(Redirected from 2C-IP)

2C-iP
Clinical data
Other names4-Isopropyl-2,5-dimethoxyphenethylamine; 2,5-Dimethoxy-4-isopropylphenethylamine; Jelena; Momento
Routes of
administration		Oral[1]
Drug classSerotonin receptor modulator; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Legal status
Legal status
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
Pharmacokinetic data
Duration of action8–12 hours[1]
Identifiers
  • 2-[2,5-dimethoxy-4-(propan-2-yl)phenyl]ethan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H21NO2
Molar mass223.316 g·mol−1
3D model (JSmol)
  • COC1=C(C=C(C(=C1)C(C)C)OC)CCN
  • InChI=1S/C13H21NO2/c1-9(2)11-8-12(15-3)10(5-6-14)7-13(11)16-4/h7-9H,5-6,14H2,1-4H3
  • Key:XUGPCRRUMVWELT-UHFFFAOYSA-N

2C-iP, also known as 4-isopropyl-2,5-dimethoxyphenethylamine or as Jelena or Momento, is a psychedelic drug of the phenethylamine and 2C families.[1][2][3] It is taken orally.[1] The drug was first described by 2011[3] and was encountered as a novel designer drug by 2018.[2]

Use and effects

[edit]

2C-iP's dose is 8 to 25 mg orally and its duration is 8 to 12 hours.[1] It is said that careful dose titration is necessary to avoid overdose.[1] The drug is said to produce a strong sense of heightened awareness of the present moment, resulting in the nickname "Momento", among other effects.[1]

Interactions

[edit]

Pharmacology

[edit]

Pharmacodynamics

[edit]

2C-iP shows affinity for the serotonin 5-HT2 receptors, including for the serotonin 5-HT2A receptor.[1]

Chemistry

[edit]

Analogues

[edit]

Analogues of 2C-iP include 2C-P, 2C-cP, 2C-iBu, 2C-tBu, 2C-D, 2C-E, 2C-T-4, and DOiP, among others.[4][1][2]

History

[edit]

2C-iP was first described in the scientific literature by Dmitri Ger and colleagues by 2011.[3] It was encountered as a novel designer drug in Sweden in 2018.[2]

Society and culture

[edit]
[edit]

Canada

[edit]

As of October 31, 2016, 2C-iP is a controlled substance (Schedule III) in Canada.[5]

United States

[edit]

2C-iP is not an explicitly controlled substance in the United States.[6] However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption. In addition, it may be considered scheduled as an isomer of 2C-P.[6]

See also

[edit]

References

[edit]
  1. 1 2 3 4 5 6 7 8 9 Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1 ed.). Solothurn: Nachtschatten-Verlag. ISBN 978-3-03788-700-4. OCLC 858805226. Archived from the original on 21 August 2025.
  2. 1 2 3 4 "2C-IP". АИПСИН (in Russian). Retrieved 1 January 2026.
  3. 1 2 3 Ger A, Ger D (1 March 2011). "Triple Goddess of the Night". British Neuroscience Association Bulletin. Archived from the original on 19 February 2014. Retrieved 16 July 2015.
  4. ↑ Shulgin A, Shulgin A (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628.
  5. ↑ "Regulations Amending the Food and Drug Regulations (Part J — 2C-phenethylamines)". Controlled Drugs and Substances Act. Government of Canada. 15 April 2016.
  6. 1 2 Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026) (PDF), United States: U.S. Department of Justice: Drug Enforcement Administration (DEA): Diversion Control Division, January 2026
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=2C-iP&oldid=1334211814"